Zobrazeno 1 - 10
of 180
pro vyhledávání: '"S. GOMBOS"'
Autor:
Anam A. Mazharuddin, Andrew T. Whyte, Dan S. Gombos, Nimisha Patel, Azadeh Razmandi, Amina L. Chaudhry, Nagham S. Al-Zubidi
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 98-104 (2022)
Introduction: Immune checkpoint inhibitors (ICIs) have improved prognosis in advanced malignancies; however, they may be associated with extensive ocular immune-related adverse events (irAEs) that are sight threatening. Our study aimed to identify th
Externí odkaz:
https://doaj.org/article/f781b5aa35b64598bbfb198113e72862
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 26, Iss , Pp 101517- (2022)
Externí odkaz:
https://doaj.org/article/e36a3415510b400ab67b5329ef45b7ed
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 6-15 (2021)
Targeted cancer therapy agents are the latest development in cancer therapeutics. Although the spectrum of their use continues to expand, ocular side effects are frequently encountered with the use of cancer therapeutics. This review describes the oc
Externí odkaz:
https://doaj.org/article/dba80401bcd44f4a9451f0390158328c
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposeEvaluate incidence of second primary malignancies (SPM) after non-acral cutaneous melanoma (NACM), acral lentiginous melanoma (ALM), mucosal melanoma (MM), and uveal melanoma (UM).Patients and MethodsFirst primary NACM, ALM, MM, and UM cases d
Externí odkaz:
https://doaj.org/article/6049095230084574a808e43972772551
Autor:
Steven H Lin, Heather Y Lin, Vivek Verma, Meng Xu-Welliver, Peter F Thall, Luyang Yao, Peter Y Kim, Dan S Gombos, Jitesh D Kawedia, Ritsuko Komaki, Daniel R Gomez, Quynh-Nhu Nguyen, Michael S O'Reilly, Charles Lu, Frank V Fossella, Ferdinandos Skoulidis, Jianjun Zhang, Anne S Tsao, John V Heymach, George R Blumenschein
Publikováno v:
Cancer Treatment and Research Communications, Vol 30, Iss , Pp 100514- (2022)
ABSTRACT: OBJECTIVE: This phase I trial (NCT01912625) evaluated the safety and pharmacokinetics of definitive concurrent chemoradiotherapy (cCRT) and the radiosensitizer trametinib (MEK1/2 inhibitor) for KRAS-mutated nonmetastatic non-small cell lung
Externí odkaz:
https://doaj.org/article/e18ec14896714573b1d9b08755f7ce93
Autor:
Kathryn Bollin, Fernando Carapeto, Kevin B Kim, Khalida M Wani, Sujan T Reddy, Michelle D Williams, Dan S Gombos, Alexander J Lazar, Sapna P Patel
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background To date, no systemic therapy, including immunotherapy, exists to improve clinical outcomes in metastatic uveal melanoma (UM) patients. To understand the role of immune infiltrates in the genesis, metastasis, and response to treatment for U
Externí odkaz:
https://doaj.org/article/3fed3b3cb79e42dfbf4d90c23d4d647c
Publikováno v:
Holland‐Frei Cancer Medicine. :1-10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6fb3ef0027a269747cd0d580fa6dfea
https://doi.org/10.1002/9781119000822.hfcm079.pub2
https://doi.org/10.1002/9781119000822.hfcm079.pub2
Autor:
Judy S. Wang, Mohsain Gill, Susanna Varkey Ulahannan, Barbara M Wirostko, Qiuqing Ang, Amita Patnaik, Dragan Cicic, Gregory Bergonio, Anushree Sharma, Dan S. Gombos, Kamran M Riaz, Cong Zhang
Publikováno v:
Canadian Journal of Ophthalmology. 57:118-126
Purpose To report 3 cases of reversible epitheliopathy induced by A166—a human epidermal growth factor receptor (HER2)-targeted antibody-drug conjugate (ADC) therapy for resistant HER2 tumours. Methods Advanced HER2 tumour patients were enrolled in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::276c3457e6bf41476256c82151e733b6
https://doi.org/10.1016/j.jcjo.2021.02.028
https://doi.org/10.1016/j.jcjo.2021.02.028
Publikováno v:
Ophthalmology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd84c251ae8435251dea5ac65d9c502e
https://doi.org/10.1016/j.ophtha.2023.01.012
https://doi.org/10.1016/j.ophtha.2023.01.012
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.